Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.
Also called NCT04680442
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 130 participants
- Registry
-
NCT04680442
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil, Canada, Russia
- Registry status
- Recruiting
Technical summary
Registry record NCT04680442. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-01 (actual); primary completion 2025-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
- Acronym
- SCHOLAR-2
- Condition
- Breast Cancer
- Condition
- Heart Failure
- Intervention (Drug)
- Trastuzumab
- Intervention (Drug)
- Pertuzumab
- Intervention (Drug)
- Trastuzumab emtansine
- Lead sponsor
- Population Health Research Institute
Record details
- Record id
cardio:ct-nct04680442- Content hash
2d923610d1e284ff8c66fa20d7c83941212f7cd4a315e3559ce6fd234a07dce4